Literature DB >> 1677643

p185HER2 signal transduction in breast cancer cells.

G K Scott1, J M Dodson, P A Montgomery, R M Johnson, J C Sarup, W L Wong, A Ullrich, H M Shepard, C C Benz.   

Abstract

A partially agonistic monoclonal antibody, 4D5, known to bind to the extracellular domain of p185HER2 and shown to inhibit long term growth of p185HER2-overexpressing breast cancer cells, was used to study signal transduction and phosphotyrosyl protein substrates associated with this receptor. Normal breast epithelial cells and breast carcinoma cells expressing low levels of p185HER2 were not affected by 4D5. HER2/neu-overexpressing breast cancer cells (BT-474 and SK-Br-3) exposed to 4D5 exhibited rapid phosphorylation of both p185HER2 and an associated 56-kDa phosphotyrosyl protein (ptyr56). Paralleling the 4D5- stimulated phosphorylation of p185HER2 and ptyr56 was a 5-10-fold induction of c-fos mRNA and phosphatidylinositol 4-kinase activity and a 2-fold induction of inositol 1,4,5-trisphosphate 3'-kinase activity. The increased phosphatidylinositol 4-kinase activity immunoprecipitated with p185HER2 and also co-eluted with ptyr56 from an antiphosphotyrosine immunoaffinity column. These results indicate that short term (less than 6 h) 4D5 activation of p185HER2 in overexpressing breast cancer cells produces agonistic-like signaling typical of homologous tyrosine kinase growth factor receptors such as epidermal growth factor receptor. The data also suggest that ptyr56 represents a novel phosphorylated substrate associated with 4D5-stimulated p185HER2.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677643

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Trastuzumab is not a tyrosine kinase inhibitor.

Authors:  Nishant Mohan; Wen Jin Wu
Journal:  Nat Rev Cardiol       Date:  2015-09-29       Impact factor: 32.419

2.  Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells.

Authors:  M A Ghetie; E M Podar; A Ilgen; B E Gordon; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

3.  Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling.

Authors:  Simone Diermeier-Daucher; Olaf Ortmann; Stefan Buchholz; Gero Brockhoff
Journal:  MAbs       Date:  2012-07-23       Impact factor: 5.857

Review 4.  Molecular predictors of response to trastuzumab and lapatinib in breast cancer.

Authors:  Francisco J Esteva; Dihua Yu; Mien-Chie Hung; Gabriel N Hortobagyi
Journal:  Nat Rev Clin Oncol       Date:  2009-12-22       Impact factor: 66.675

5.  ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency.

Authors:  H A Lane; I Beuvink; A B Motoyama; J M Daly; R M Neve; N E Hynes
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

6.  Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.

Authors:  Cary D Austin; Ann M De Mazière; Paul I Pisacane; Suzanne M van Dijk; Charles Eigenbrot; Mark X Sliwkowski; Judith Klumperman; Richard H Scheller
Journal:  Mol Biol Cell       Date:  2004-09-22       Impact factor: 4.138

7.  A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells.

Authors:  G K Scott; R Robles; J W Park; P A Montgomery; J Daniel; W E Holmes; J Lee; G A Keller; W L Li; B M Fendly
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

8.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu.

Authors:  C C Benz; G K Scott; J C Sarup; R M Johnson; D Tripathy; E Coronado; H M Shepard; C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

9.  Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.

Authors:  M K Webster; D J Donoghue
Journal:  EMBO J       Date:  1996-02-01       Impact factor: 11.598

Review 10.  Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.

Authors:  Kyu Sic You; Yong Weon Yi; Jeonghee Cho; Jeong-Soo Park; Yeon-Sun Seong
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.